Episodios

  • Relacorilant

    Relacorilant
    Apr 9 2026
    Discussing the new nab-paclitaxel adjunctive medication, relacorilant, for ovarian cancer. As a glucoCORticoid receptor antagonist, it is hard to pronounce. Also, a 10-year follow-up study of ibrutinib provides big picture insight on the impact of the BTKi era in CLL. Link: https://doi.org/10.1182/blood.2025029971 Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm
    Más Menos
    15 m
  • HOPA 2026 Recap

    HOPA 2026 Recap
    Apr 2 2026
    Recapping what I learned at HOPA 2026: -Beyond steroids for irAs -IT chemo beyond methotrexate and cytarabine -Pre-emptive CMV management in patients receiving certain bispecifics -semaglutide-alectinib drug interaction -Safety (n = ~40) of MMR vaccine in patients post-Auto transplant on maintenance daratumumab Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm
    Más Menos
    14 m
  • Nivo-AVD Approval

    Nivo-AVD Approval
    Mar 24 2026
    Nivolumab-AVD is finally approved for Hodgkin Lymphoma, and primary G-CSF prophylaxis is recommended (?) in the PI. Also, brief NOLA preview for HOPA attendees. The Big Easy Debate: sazerac or hurricane? Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm
    Más Menos
    10 m
  • Tazemetostat Withdrawl and RECITE

    Tazemetostat Withdrawl and RECITE
    Mar 19 2026
    Tazemetostat is withdrawn from the market due to a risk of secondary malignancies. RECITE asks if romiplostim improves platelet counts for patients on oxaliplatin-based regimens with thrombocytopenia. Spoiler - yes it does, but does that make a difference? Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm
    Más Menos
    15 m
  • FDA Approval Updates Galore

    FDA Approval Updates Galore
    Mar 12 2026
    Lots of FDA approval updates to discuss from the past few weeks: -Zongertinib gets approved in 1st line setting for ERBB2 TKD mutated metastatic NSLCLC -Encorafenib approval with cetuximab + FOLFOX -Teclistamab + Daratumumab approved in 2nd line setting for r/r multiple myeloma -Acalabrutinib + venetoclax (but NOT acalabrutinib + venetoclax + obinutuzumab) is approved for CLL Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm
    Más Menos
    13 m
  • BR.31 & ASCO GU '26

    BR.31 & ASCO GU '26
    Mar 5 2026
    This week discuss BR.31 trial of adjuvant durvalumab in NSCLC and put it into the context of the positive studies with atezolizumab and pembrolizumab. We also highlight 2 notable presentations at ASCO GU 2026 on perioperative enfortumab vedotin + pembrolizumab in cisplatin-eligible patients with resectable bladder cancer (KEYNOTE-B15) and advjuant pembrolizumab + belzutifan in RCC (LITESPARK-022) Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm
    Más Menos
    18 m
  • Rezatapopt and Colchicine for Trametnib/Dabrafenib Pyrexia

    Rezatapopt and Colchicine for Trametnib/Dabrafenib Pyrexia
    Feb 26 2026
    An exciting new drug, rezatapopt, may be effective in restoring p53 activity in cancers - a possible major therapeutic breakthrough. Can colchicine treat pyrexia from tremetinib & dabrafenib use? This case series says - maybe: https://doi.org/10.1007/s00520-019-4654-2 Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm
    Más Menos
    16 m
  • Perioperative Enortumab vedotin + Pembrolizumab

    Perioperative Enortumab vedotin + Pembrolizumab
    Feb 19 2026
    The EV-303 trial that led to the FDA approval of perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible bladder cancer patients in now published in NEJM. We discuss the results and ponder potential future changes to treating bladder cancer in the future. Urinary diversion surgeries: https://jamanetwork.com/journals/jamaoncology/fullarticle/2842595
    Más Menos
    17 m